Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Earnings Data
Report Date
Feb 10, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
1.92Last Year’s EPS
1.9Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the HIV portfolio and successful launches of new products like Yeztugo, boosting revenue expectations despite challenges in oncology and cell therapy segments. The overall sentiment is positive, driven by strong commercial execution and strategic advancements.Company Guidance
Strong HIV Portfolio Performance
HIV therapies saw impressive growth with Biktarvy up 6% year-over-year, Descovy up 20% year-over-year, and a 35% sequential growth for Livdelzi. Overall, HIV sales increased 4% versus the prior year.
Yeztugo Launch Success
Yeztugo achieved 75% payer coverage nearly 3 months ahead of schedule, contributing $39 million in sales for Q3, indicating a strong start for the new HIV prevention therapy.
Rising Revenue Expectations
Gilead increased its full-year HIV revenue growth expectations to approximately 5% despite a $900 million headwind from the Medicare Part D redesign.
Livdelzi Growth
Livdelzi sales reached over $100 million for the first time, showing a 12% year-over-year growth in the liver portfolio.
Trodelvy Advancements
Trodelvy demonstrated a 38% reduction in disease progression or death in first-line metastatic triple-negative breast cancer patients, with regulatory decisions expected in 2026.
GILD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GILD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | $118.44 | $119.79 | +1.14% |
Aug 07, 2025 | $109.52 | $118.59 | +8.28% |
Apr 24, 2025 | $104.67 | $101.74 | -2.80% |
Feb 11, 2025 | $94.14 | $101.16 | +7.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gilead Sciences (GILD) report earnings?
Gilead Sciences (GILD) is schdueled to report earning on Feb 10, 2026, After Close (Confirmed).
What is Gilead Sciences (GILD) earnings time?
Gilead Sciences (GILD) earnings time is at Feb 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GILD EPS forecast?
GILD EPS forecast for the fiscal quarter 2025 (Q4) is 1.92.